Condition
Angioid Streaks
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 3 (1)
Trial Status
Withdrawn2
Terminated1
Completed1
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07048106Recruiting
Progression Assessment of PXE-associated Alterations
NCT00599820Phase 3TerminatedPrimary
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
NCT00406250Phase 1CompletedPrimary
Intravitreal Bevacizumab in Agioid Streaks
NCT01256580Not ApplicableWithdrawn
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT01015495Phase 1WithdrawnPrimary
Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
Showing all 5 trials